Sareum : Details of Investor Presentation

12 August 2020

Sareum Holdings PLC

('Sareum' or the 'Company')

Investor Presentation

Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that, further to yesterday's trading update, Dr Tim Mitchell will deliver a live online presentation to investors via the Investor Meet Company ('IMC') platform at 10.00am on Friday, 14 August 2020.

Existing and potential investors wishing to participate in the presentation must register with IMC at: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor. Investors who have already registered with IMC and requested to meet the Company will be invited automatically.

Questions can be submitted before the event via the IMC dashboard or at any time during the live presentation via the 'Ask a Question' function. Although the Company may not be able to answer every question it receives, it will seek to address the most prominent questions within the confines of information already disclosed to the market. Responses from the Q&A session will be published at the earliest opportunity on the IMC platform.

A copy of the presentation will be made available on the Company's website following the presentation.

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO 01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / Richard Tulloch 020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce / John Beresford-Peirse 020 3764 2341

Citigate Dewe Rogerson (Financial PR)

Mark Swallow/ David Dible 020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802). The Company is targeting completion of IND-enabling studies for at least one of these candidates in 2020.

The Company's preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a China-based specialty pharma company.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra is currently exploring options to obtain the funding or support necessary to advance the future development of SRA737.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com.